WebBio-Techne's Mission is to build Epic Tools for Epic Science. We have a creative, caring team of colleagues throughout the world who bring unique perspectives and talents in support of that Mission and who embody our … Web1 day ago · MINNEAPOLIS, April 13, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell...
Q4 and full-year 2024 results
WebApr 13, 2024 · Poster Presentations: An exosome-based ESR1 monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at ≤0.1% frequency in liquid biopsy samples Tuesday, April 18 th from 9:00 AM – 12:30 PM EDT Presenter: Gary Latham, Ph. D. Section 37, Poster Board #29, Abstract #4354 WebMar 17, 2024 · Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March ... the longleaf hotel reviews
TECH: Bio-Techne Corp - Stock Price, Quote and News - CNBC
WebJan 11, 2024 · 2024 Investor Day Presentation . Jun 29, 2024. Bio-Techne to Acquire Exosome Diagnostics . Sep 15, 2016. 2016 Investor Day Presentation . Email Alerts; … Business Description. Bio-Techne Corporation (NASDAQ: TECH) is a … Learn about our life science & clinical diagnostic brands including R&D … Latest Presentation. January 11, 2024. Corporate Presentation - January 2024 … Press Releases - Presentations :: Bio-Techne Corporation (TECH) Annual Reports - Presentations :: Bio-Techne Corporation (TECH) Financial Results - Presentations :: Bio-Techne Corporation (TECH) IR Calendar - Presentations :: Bio-Techne Corporation (TECH) All SEC Filings - Presentations :: Bio-Techne Corporation (TECH) Financial Information - Presentations :: Bio-Techne Corporation (TECH) Stock Data - Presentations :: Bio-Techne Corporation (TECH) WebMar 31, 2024 · As of March 31, 2024, BIO-TECHNE Corp had a $11.4 billion market capitalization, putting it in the 89th percentile of companies in the Biotechnology & Medical Research industry. Currently, BIO-TECHNE Corp’s price-earnings ratio is 46.2. BIO-TECHNE Corp’s trailing 12-month revenue is $1.1 billion with a 23.4% profit margin. WebDec 31, 2024 · Corporate Presentation - January 2024 View Presentation View All. Latest Quarterly Results. Q2 2024. Quarter Ended Dec 31, 2024. PDF HTML Earnings … ticking under the hood